Publications

Publications

ARTICLE

Development of a Potent Nurr1 Agonist Tool for In Vivo Applications

Jan Vietor, Christian Gege, Tanja Stiller, Romy Busch, Espen Schallmayer, Hella Kohlhof, Georg Höfner, Jörg Pabel, Julian A. Marschner, and Daniel Merk*
Journal of Medicinal Chemistry
Published: April 26, 2023
https://doi.org/10.1021/acs.jmedchem.3c00415

POSTER PRESENTATION

Digestive Disease Week 2023

Saturday, May 6, 2023 Tuesday, May 9, 2023

PRESENTATION

7th ISIRV-AVG Conference, Advancing Respiratory Virus Therapeutics: Lessons Learned from COVID-19

Wednesday, May 3, 2023 – Friday, May 5, 2023

ARTICLE

Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study

Thomas M. Polasek, Indika Leelasena, Irina Betscheider, Marija Marolt, Hella Kohlhof, Daniel Vitt, Frank Fliegert, Andreas R. Muehler
Clinical Pharmacology in Drug Development
Published: March 20, 2023
https://doi.org/10.1002/cpdd.1243

PRESENTATION

Outsourcing in Clinical Trials DACH 2022

Wednesday, November 30, 2022Thursday, December 1, 2022

POSTER PRESENTATION

Australasian Pharmaceutical Science Association (APSA) and Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) 2022 Joint Conference

Tuesday, November 29, 2022Friday, December 2, 2022

ARTICLE

Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective Modulators

Jan Heering, Nathalie Jores, Whitney Kilu, Espen Schallmayer, Evelyn Peelen, Andreas Muehler, Hella Kohlhof, Daniel Vitt, Verena Linhard, Santosh L. Gande, Apirat Chaikuad, Sridhar Sreeramulu, Harald Schwalbe, Daniel Merk
ACS Chemical Biology
Published: November 1, 2022
https://doi.org/10.1021/acschembio.2c00599

PRESENTATION

38th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

Wednesday, October 26, 2022 – Friday, October 28, 2022

POSTER PRESENTATION

19th International Celiac Disease Symposium (ICDS)

Wednesday, October 19, 2022 – Saturday, October 22, 2022

ARTICLE

Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial

Maria J. G. T. Vehreschild, Petar Atanasov, Kateryna Yurko, Cristian Oancea, Georgi Popov, Valentina Smesnoi, Gheorghe Placinta, Hella Kohlhof, Daniel Vitt, Evelyn Peelen, Jelena Mihajlović, Andreas R. Muehler
Infectious Diseases and Therapy
Published: October 15, 2022
https://doi.org/10.1007/s40121-022-00690-0

PRESENTATION

B & T Cell-Mediated Autoimmune Disease Drug Development Summit

Tuesday, July 26, 2022 – Thursday, July 28, 2022

ARTICLE

A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis

Robert J. Fox, Heinz Wiendl, Christian Wolf, Nicola De Stefano, Johann Sellner, Viktoriia Gryb, Konrad Rejdak, Plamen Stoyanov Bozhinov, Nataliya Tomakh, Iryna Skrypchenko, Andreas R. Muehler
Annals of Clinical and Translational Neurology
Published: June 14, 2022
https://doi.org/10.1002/acn3.51574

ARTICLE

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication

Kim M. Stegmann et al.
iScience
Published: May 20, 2022
https://doi.org/10.1016/j.isci.2022.104293

 

ARTICLE

A Pilot Study of Vidofludimus Calcium for Treatment of Primary Sclerosing Cholangitis

Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. Lindor
Hepatology Communications
Published: March 3, 2022
https://doi.org/10.1002/hep4.1926

POSTER PRESENTATION

17th Congress of ECCO (European Crohn’s and Colitis Organization)

Wednesday, February 16, 2022 – Saturday, February 19, 2022

POSTER PRESENTATION

50th Annual European Society for Dermatological Research (ESDR) Meeting

Wednesday, September 22, 2021 – Saturday, September 25, 2021

POSTER PRESENTATION

The International Federation of Psoriasis Association’s 6th World Psoriasis & Psoriatic Arthritis Conference 2021

Wednesday, June 30, 2021 – Saturday, July 3, 2021

POSTER PRESENTATION

30th Annual Meeting of the Society for Virology

Wednesday, March 24, 2021 – Friday, March 26, 2021

ARTICLE

Clinical Relevance of Intestinal Barrier Dysfunction in Common Gastrointestinal Diseases

Andreas Muehler, Jason R. Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt
World Journal of Gastrointestinal Pathophysiology
Published: December 12, 2020
https://doi.org/10.4291/wjgp.v11.i6.114

ARTICLE

IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro

Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Brett Hurst, Justin Julander, Jonas Fuchs, Zsolt Ruzsics, Klaus Überla, Hans-Martin Jäck, Roger Ptak, Andreas Muehler, Manfred Gröppel, Daniel Vitt, Evelyn Peelen, Hella Kohlhof, Manfred Marschall
Viruses
Published: December 5, 2020
https://doi.org/10.3390/v12121394

ARTICLE

Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity Against Mammarenaviruses In Vitro

Yu-Jin Kim, Beatrice Cubitt, Yingyun Cai, Jens H. Kuhn, Daniel Vitt, Hella Kohlhof, Juan C. de la Torre
Viruses
Published: July 29, 2020
https://doi.org/10.3390/v12080821

ARTICLE

Vidofludimus Calcium, a Next Generation DHODH Inhibitor for the Treatment of Relapsing-Remitting Multiple Sclerosis

Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt
Multiple Sclerosis and Related Disorders
Published: May 6, 2020
https://doi.org/10.1016/j.msard.2020.102129

ARTICLE

Safety, Tolerability and Pharmacokinetics of Vidofludimus Calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects

Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
European Journal of Drug Metabolism and Pharmacokinetics
Published: May 2, 2020
https://doi.org/10.1007/s13318-020-00623-7

ABSTRACT

Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)

Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Mühler
Neurology
Published: April 14, 2020

POSTER PRESENTATION

United European Gastroenterology Week (UEGW)

Tuesday, October 22, 2019
Barcelona, Spain

ARTICLE

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study

Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
Drugs in R&D
Published: October 16, 2019
https://doi.org/10.1007/s40268-019-00286-z

POSTER PRESENTATION

Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019

Wednesday, September 11, 2019
Stockholm, Sweden

.